Sonoma Pharmaceuticals (SNOA) Competitors $3.30 +0.05 (+1.38%) As of 03:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNOA vs. CGTX, QTTB, NNVC, NAII, XFOR, LSTA, PASG, VYNE, LEXX, and CMMBShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include Cognition Therapeutics (CGTX), Q32 Bio (QTTB), NanoViricides (NNVC), Natural Alternatives International (NAII), X4 Pharmaceuticals (XFOR), Lisata Therapeutics (LSTA), Passage Bio (PASG), VYNE Therapeutics (VYNE), Lexaria Bioscience (LEXX), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. Cognition Therapeutics Q32 Bio NanoViricides Natural Alternatives International X4 Pharmaceuticals Lisata Therapeutics Passage Bio VYNE Therapeutics Lexaria Bioscience Chemomab Therapeutics Cognition Therapeutics (NASDAQ:CGTX) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation. Which has preferable earnings & valuation, CGTX or SNOA? Sonoma Pharmaceuticals has higher revenue and earnings than Cognition Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCognition TherapeuticsN/AN/A-$25.79M-$0.74-0.42Sonoma Pharmaceuticals$13.97M0.38-$4.84M-$4.02-0.82 Is CGTX or SNOA more profitable? Cognition Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -26.82%. Sonoma Pharmaceuticals' return on equity of -68.98% beat Cognition Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cognition TherapeuticsN/A -150.93% -100.82% Sonoma Pharmaceuticals -26.82%-68.98%-26.39% Does the media refer more to CGTX or SNOA? In the previous week, Sonoma Pharmaceuticals had 1 more articles in the media than Cognition Therapeutics. MarketBeat recorded 1 mentions for Sonoma Pharmaceuticals and 0 mentions for Cognition Therapeutics. Sonoma Pharmaceuticals' average media sentiment score of 0.75 beat Cognition Therapeutics' score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Cognition Therapeutics Neutral Sonoma Pharmaceuticals Positive Which has more volatility and risk, CGTX or SNOA? Cognition Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Sonoma Pharmaceuticals has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Does the MarketBeat Community prefer CGTX or SNOA? Sonoma Pharmaceuticals received 191 more outperform votes than Cognition Therapeutics when rated by MarketBeat users. However, 73.53% of users gave Cognition Therapeutics an outperform vote while only 67.50% of users gave Sonoma Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCognition TherapeuticsOutperform Votes2573.53% Underperform Votes926.47% Sonoma PharmaceuticalsOutperform Votes21667.50% Underperform Votes10432.50% Do analysts rate CGTX or SNOA? Cognition Therapeutics presently has a consensus price target of $6.13, indicating a potential upside of 1,869.45%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cognition Therapeutics is more favorable than Sonoma Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in CGTX or SNOA? 43.3% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 20.8% of Cognition Therapeutics shares are held by company insiders. Comparatively, 3.9% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryCognition Therapeutics beats Sonoma Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.33M$4.44B$5.34B$8.44BDividend YieldN/A43.63%5.21%4.11%P/E Ratio-0.8229.3326.9019.78Price / Sales0.3865.82389.48118.91Price / CashN/A51.0838.2534.62Price / Book1.096.216.784.52Net Income-$4.84M$67.60M$3.23B$248.23M7 Day Performance3.62%-0.19%2.02%0.81%1 Month Performance41.42%18.57%10.97%13.32%1 Year Performance1,767.91%22.24%17.38%7.69% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma Pharmaceuticals0.2323 of 5 stars$3.30+1.4%N/A+1,533.2%$5.33M$13.97M-0.82180CGTXCognition Therapeutics2.5473 of 5 stars$0.33+8.6%$6.13+1,773.7%-86.0%$20.26MN/A-0.3420Gap UpQTTBQ32 Bio2.1195 of 5 stars$1.66+7.1%$24.71+1,388.8%-94.5%$20.25M$-6,651,000.00-0.1239NNVCNanoViricidesN/A$1.28-3.0%N/A-33.6%$20.04MN/A-1.7820News CoverageNAIINatural Alternatives International0.7338 of 5 stars$3.22-0.3%N/A-49.7%$19.96M$121.85M-2.50290News CoveragePositive NewsAnalyst ForecastXFORX4 Pharmaceuticals4.5774 of 5 stars$3.34-0.9%$72.33+2,065.7%-89.7%$19.51M$31.36M-37.1180LSTALisata Therapeutics2.7981 of 5 stars$2.23+6.2%$15.00+572.3%-16.9%$19.22M$1M-0.8930PASGPassage Bio2.1131 of 5 stars$0.31-6.3%$7.50+2,332.7%-76.5%$19.16MN/A-0.26130Gap UpVYNEVYNE Therapeutics1.9633 of 5 stars$1.25-3.8%$6.25+400.0%-63.0%$19.01M$501,000.00-1.4530Analyst DowngradeGap UpHigh Trading VolumeLEXXLexaria Bioscience2.0166 of 5 stars$1.08-0.5%$7.00+551.2%-67.9%$18.88M$525,923.00-2.157CMMBChemomab Therapeutics3.3119 of 5 stars$1.24-1.6%$9.00+625.8%+68.3%$17.81MN/A-1.2420Earnings Report Related Companies and Tools Related Companies Cognition Therapeutics Competitors Q32 Bio Competitors NanoViricides Competitors Natural Alternatives International Competitors X4 Pharmaceuticals Competitors Lisata Therapeutics Competitors Passage Bio Competitors VYNE Therapeutics Competitors Lexaria Bioscience Competitors Chemomab Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNOA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SNOA Stock Free SNOA Stock Alerts